Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials for Non-Small Cell Lung Cancer (NSCLC)

40 trials tracked for Non-Small Cell Lung Cancer (NSCLC): 13 in phase 3 or 4 and 8 with published results. The most-cited published study has 6553 citations.

40Trials tracked
13Phase 3 & 4
0Recruiting
8With published results
Phase distribution
Phase 4 3 Phase 3 10 Phase 2 17 Phase 1 5 Other / NA 5
  1. Phase 3 Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010) Completed · 6,553 cited
  2. Phase 3 A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Completed · 187 cited
  3. Phase 3 A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients Completed · 185 cited
  4. Phase 3 A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Completed · 163 cited
  5. Phase 3 A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery Completed · 43 cited
  6. Phase 3 A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Treatment of Physician's Choice in Subjects With Advanced Non-Small Cell Lung Cancer Completed · 18 cited
Show 34 more trials
  1. Phase 4 Osimertinib Study in Indian Patients Completed · 5 cited
  2. Phase 3 A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer Completed
  3. Phase 4 Study of Nivolumab for Advanced Cancers in India Completed
  4. Phase 4 Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC) Completed
  5. Phase 3 A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) Completed
  6. Phase 3 Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) Completed
  7. Phase 3 Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX) Completed
  8. Phase 2 The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial Completed
  9. Phase 2 Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration Completed
  10. Phase 2 Phase 2 Trial of Bevacizumab in Combination With Pemetrexed Completed
  11. Phase 2 Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer Completed
  12. Phase 2 FLT3 Ligand Immunotherapy and Stereotactic Radiotherapy for Advanced Non-small Cell Lung Cancer Completed
  13. Phase 2 A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients Completed
  14. Phase 2 A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Completed
  15. Phase 2 Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer Completed
  16. Phase 2 Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC) Completed
  17. Phase 2 Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC Completed
  18. Phase 2 Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC) Completed
  19. Phase 2 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer Completed
  20. Phase 2 Single Arm on the Tolerability of Weekly Nab-paclitaxel Completed
  21. Phase 2 Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO Completed
  22. Phase 2 Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors Completed
  23. Phase 2 A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients Completed
  24. Phase 2 Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation Completed
  25. Phase 1 Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer Completed
  26. Phase 1 Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer Completed
  27. Phase 1 A Dose Escalation and Expansion Study of Lomvastomig, a PD-1/TIM-3 Bispecific Antibody, in Participants With Advanced and/or Metastatic Solid Tumors Completed
  28. Phase 1 Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC) Completed
  29. Phase 1 Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer Completed
  30. N/A Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR) Completed
  31. N/A Evaluation of a Powered Surgical Stapler in Video-Assisted Thoracoscopic Lung Resection Procedures in Korea Completed
  32. N/A Prognostic Value of Tumor Hypoxia, as Measured by 18F-FMISO Breath Hold PET/CT, in Non-Small-Cell-Lung Cancer (NSCLC) Patients Completed
  33. N/A Powered Echelon Device in VATS Surgery Completed
  34. N/A Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer Completed

Showing the 40 most-cited and recently-updated of 40 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Non-Small Cell Lung Cancer (NSCLC): what the trials found

Several immunotherapies have demonstrated clinical activity in NSCLC. Pembrolizumab showed significant improvements in both overall survival (OS) and progression-free survival (PFS) 7, with a high rate of adverse events reported across study arms 7. In other trials, Nivolumab was evaluated for safety and efficacy; while specific grade 3-5 treatment-related adverse events were recorded 8, the drug also showed consistent results in large-scale assessments regarding progression-free survival 11. Durvalumab demonstrated a measurable percentage of patients remaining progression-free at 12 months 22 and was evaluated for safety profiles involving high-grade treatment-related adverse events [20, 22].

Atezolizumab showed no statistically significant difference in PFS in the PD-L1 positive analysis set or the full analysis set 1. Tiragolumab demonstrated a statistically significant improvement in investigator-assessed PFS specifically in patients with PD-L1 expression at TPS/TC >=1% 2, though it did not reach significance in other primary endpoints like OS 2. Other targeted therapies included Crizotinib, which showed a significant improvement in PFS and objective response rate (ORR) compared to the control arm, despite no significant difference in overall survival 9.

Combination therapies also provided evidence for NSCLC management. The combination of cetuximab with cisplatin and vinorelbine significantly improved both OS and best overall response rate 14, whereas the addition of cetuximab to a platinum-based doublet chemotherapy did not show statistically significant improvements in OS or time to treatment failure 13. Other established agents include Osimertinib 4, Nivolumab 5, Gefitinib 6, and Eribulin, though the latter did not reach statistical significance for OS, PFS, or ORR 12.

Recent results — preliminary, needs further review

  • Capmatinib showed a range of changes from baseline in NCCN FACT-FBrSI total composite scores (7.0; 2.1; 6.5; 2.1; -3.0; -1.7) 3. MEDI4736 (anti-PD-L1) was evaluated in a Phase 2 trial 15.

For the clinician treating this condition

  • Pembrolizumab is associated with significant improvements in both OS and PFS, though it is associated with high rates of adverse events 7.
  • Crizotinib demonstrated superior progression-free survival and objective response rates compared to control, despite non-significant overall survival outcomes 9.
  • Tiragolumab showed statistically significant improvement in investigator-assessed PFS specifically in the PD-L1 positive population (TPS/TC >=1%) 2.

AI synthesis of 15 cited trials, updated Jul 30, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients
Oncology Sys. Review
Local therapy and intrathecal chemotherapy may manage CNS progression in EGFR-mutant NSCLC patients Combined Treatments May Help Manage Brain Metastases in Lung Cancer
This case report and literature review describes a patient with EGFR-mutant NSCLC and brain/leptomeningeal metastases. The authors suggest t…
A new treatment approach combining surgery, local chemotherapy, and targeted drugs may help manage brain cancer spread for some patients.
Frontiers Jul 30, 2026